University of California San Francisco

Emily Bergsland, M.D.
Emily Bergsland, MD

Professor of Clinical Medicine
Division of Hematology Oncology
Department of Medicine
Ernest Rosenbaum, MD Endowed Chair of Medical Oncology

Address

550 16th Street, #6804
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-353-9888
Fax: 415-353-7984

Biography

Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California (UCSF) Molecular Medicine Training Program 06/1998
University of California (UCSF) Fellowship Medical Oncology 06/1995
University of California (UCSF) Chief Residency 06/1993
University of California (UCSF) Residency Internal Medicine 06/1992
University of Minnesota MD Medicine 06/1989
University of Wisconsin BS Biochemistry/Molecular Biology 05/1985

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty

Clinical Expertise

Colon Cancer
Esophageal Cancer
Liver Cancer
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Clinical Trials

  1. Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors (NCT05746208)
    Related Conditions: Neuroendocrine Tumor, Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
  2. Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (NCT05746182)
    Related Conditions: Pancreatic Neuroendocrine Neoplasm, Neoplasms, Neuroendocrine Tumor| Start Date: | End Date:
  3. Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas (NCT03136055)
    Related Conditions: Neuroendocrine Carcinoma, Carcinoma| Start Date: | End Date:
  4. RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (NCT00843531)
    Related Conditions: Neuroendocrine Tumor| Start Date: | End Date:
  5. Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (NCT00227617)
    Related Conditions: Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor, Neoplasms, Gastrointestinal Cancer| Start Date: | End Date:
  6. Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors (NCT00390156)
    Related Conditions: Solid Tumor, Neoplasms| Start Date: | End Date:

Grants and Funding

  • UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology | NIH | 2021-07-01 - 2026-06-30 | Role: Principal Investigator

Research Interests

Angiogenesis Inhibitors 
Pancreatic Neoplasms 
Vascular Endothelial Growth Factor
Colorectal Neoplasms 
Neuroendocrine Tumors 

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 158
  1. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling.
    Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Le BK, Shih BE, Whitman J, Bergsland E| | PubMed
  2. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  3. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
    Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S| | PubMed
  4. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
    Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN| | PubMed
  5. Metastatic insulinoma-outcomes in the current era.
    Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E| | PubMed
  6. Withdrawal pain following patients discontinuing Trk inhibitors.
    Chin A, Lindsay S, Bergsland EK, Kang H| | PubMed
  7. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR| | PubMed
  8. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P| | PubMed
  9. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  10. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C| | PubMed
158
View all 158 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 158
  1. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling.
    Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Le BK, Shih BE, Whitman J, Bergsland E| | PubMed
  2. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  3. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
    Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S| | PubMed
  4. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
    Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN| | PubMed
  5. Metastatic insulinoma-outcomes in the current era.
    Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E| | PubMed
  6. Withdrawal pain following patients discontinuing Trk inhibitors.
    Chin A, Lindsay S, Bergsland EK, Kang H| | PubMed
  7. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR| | PubMed
  8. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P| | PubMed
  9. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  10. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C| | PubMed
  11. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K| | PubMed
  12. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
    Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA| | PubMed
  13. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
    Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I| | PubMed
  14. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.
    Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ| | PubMed
  15. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK| | PubMed
  16. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
    Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants| | PubMed
  17. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.
    Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S| | PubMed
  18. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.
    Varghese DG, Del Rivero J, Bergsland E| | PubMed
  19. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA| | PubMed
  20. Preclinical Models of Adrenocortical Cancer.
    Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J| | PubMed
  21. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
    Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK| | PubMed
  22. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK| | PubMed
  23. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
    Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR| | PubMed
  24. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
    Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A| | PubMed
  25. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM| | PubMed
  26. Preclinical Models of Neuroendocrine Neoplasia.
    Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J| | PubMed
  27. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M| | PubMed
  28. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
    Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN| | PubMed
  29. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E| | PubMed
  30. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
    Hope TA, Pavel M, Bergsland EK| | PubMed
  31. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
    Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M| | PubMed
  32. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA| | PubMed
  33. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
    Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP| | PubMed
  34. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S| | PubMed
  35. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S| | PubMed
  36. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C| | PubMed
  37. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M| | PubMed
  38. The Immunotherapy Landscape in Adrenocortical Cancer.
    Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J| | PubMed
  39. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
    Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH| | PubMed
  40. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K| | PubMed
  41. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK| | PubMed
  42. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
    Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M| | PubMed
  43. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
    Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA| | PubMed
  44. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
    Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S| | PubMed
  45. Carcinoid Crisis-Induced Acute Systolic Heart Failure.
    Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW| | PubMed
  46. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC| | PubMed
  47. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
    Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA| | PubMed
  48. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of
    Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E| | PubMed
  49. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
    Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR| | PubMed
  50. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
    Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K| | PubMed
  51. Reply to S. Boutayeb et al.
    Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY| | PubMed
  52. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
    Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA| | PubMed
  53. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.
    Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY| | PubMed
  54. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA| | PubMed
  55. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  56. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
    Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J| | PubMed
  57. A Rare Case of Carcinoid Constrictive Pericarditis.
    Wang TS, Bergsland EK, Zhang R, Ihnken K, Tolstrup K| | PubMed
  58. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  59. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
    Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E| | PubMed
  60. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K| | PubMed
  61. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
    Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P| | PubMed
  62. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  63. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
    Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA| | PubMed
  64. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  65. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N| | PubMed
  66. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K| | PubMed
  67. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
    Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W| | PubMed
  68. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  69. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH| | PubMed
  70. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK| | PubMed
  71. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
    Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E, Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group| | PubMed
  72. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  73. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM| | PubMed
  74. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.
    Mulvey CK, Bergsland EK| | PubMed
  75. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
    Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G| | PubMed
  76. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
    Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH| | PubMed
  77. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
    Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB| | PubMed
  78. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
    Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR| | PubMed
  79. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
    Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP| | PubMed
  80. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
    Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK| | PubMed
  81. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF| | PubMed
  82. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
    Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK| | PubMed
  83. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
    Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E| | PubMed
  84. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA| | PubMed
  85. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK| | PubMed
  86. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP| | PubMed
  87. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK| | PubMed
  88. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
    Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M| | PubMed
  89. A phase II study of axitinib in advanced neuroendocrine tumors.
    Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK| | PubMed
  90. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J| | PubMed
  91. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK, Bergsland EK| | PubMed
  92. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
    Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R| | PubMed
  93. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK| | PubMed
  94. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E| | PubMed
  95. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
    Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN| | PubMed
  96. Transcatheter pulmonic valve replacement in carcinoid heart disease.
    Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK| | PubMed
  97. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G| | PubMed
  98. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?
    Bergsland EK| | PubMed
  99. Is more not better?: combination therapies in colorectal cancer treatment.
    Bergsland EK| | PubMed
  100. Neuroendocrine tumors, version 1.2015.
    Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D, National comprehensive cancer network| | PubMed
  101. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
    Klimstra DS, Beltran H, Lilenbaum R, Bergsland E| | PubMed
  102. Bone metastases and skeletal-related events from neuroendocrine tumors.
    Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK| | PubMed
  103. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    Bergsland EK, Nakakura EK| | PubMed
  104. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
    Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A| | PubMed
  105. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
    Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM| | PubMed
  106. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP| | PubMed
  107. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
    Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK| | PubMed
  108. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK| | PubMed
  109. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  110. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP| | PubMed
  111. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.
    Bergsland EK| | PubMed
  112. The evolving landscape of neuroendocrine tumors.
    Bergsland EK| | PubMed
  113. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA| | PubMed
  114. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  115. Neuroendocrine tumors.
    Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA, National Comprehensive Cancer Networks| | PubMed
  116. Systemic therapy for advanced carcinoid tumors: where do we go from here?
    Paulson AS, Bergsland EK| | PubMed
  117. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM| | PubMed
  118. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
    Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium| | PubMed
  119. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
    Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC| | PubMed
  120. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  121. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  122. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  123. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA| | PubMed
  124. Glycemic control in patients with insulinoma treated with everolimus.
    Kulke MH, Bergsland EK, Yao JC| | PubMed
  125. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  126. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA| | PubMed
  127. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS| | PubMed
  128. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA| | PubMed
  129. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | PubMed
  130. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L| | PubMed
  131. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ| | PubMed
  132. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H| | PubMed
  133. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Nakakura EK, Venook AP, Bergsland EK| | PubMed
  134. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    Nakakura EK, Bergsland EK| | PubMed
  135. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA| | PubMed
  136. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS| | PubMed
  137. Pancreatoblastoma in an adult: case report and review of the literature.
    Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK| | PubMed
  138. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H| | PubMed
  139. When does the presence of the target predict response to the targeted agent?
    Bergsland EK| | PubMed
  140. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | PubMed
  141. Anti-angiogenic strategies in gastrointestinal malignancies.
    Whisenant J, Bergsland E| | PubMed
  142. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA| | PubMed
  143. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S| | PubMed
  144. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM| | PubMed
  145. Update on clinical trials targeting vascular endothelial growth factor in cancer.
    Bergsland EK| | PubMed
  146. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK| | PubMed
  147. Angiogenesis in colorectal cancer: therapeutic implications and future directions.
    Allen J, Bergsland EK| | PubMed
  148. Maximizing the potential of bevacizumab in cancer treatment.
    Bergsland E, Dickler MN| | PubMed
  149. Couples therapy at end of life.
    Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S| | PubMed
  150. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D| | PubMed
  151. Immune enhancement of skin carcinogenesis by CD4+ T cells.
    Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D| | PubMed
  152. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E| | PubMed
  153. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.
    Ko AH, Bergsland EK, Lee GA| | PubMed
  154. Shedding old paradigms: developing viruses to treat cancer.
    Bergsland EK, Venook AP| | PubMed
  155. Molecular mechanisms underlying the development of hepatocellular carcinoma.
    Bergsland EK| | PubMed
  156. Hepatocellular carcinoma.
    Bergsland EK, Venook AP| | PubMed
  157. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
    Hanahan D, Bergers G, Bergsland E| | PubMed
  158. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.
    Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM| | PubMed